IperionX Doubles Its Loss to $66.8 Million as the Titanium Buildout Eats Cash
Published on 10/02/2026 at 14:32 | Editorial boerse-global.de
Western governments have made no secret of their desire to sever strategic dependence on foreign critical minerals, and titanium sits near the top of that wish list. Aerospace and defense demand is robust. Yet turning a domestic supply chain from blueprint into tonnage remains a grinding marathon — and the capital markets are being asked to fund the early, unglamorous miles.
That tension is precisely what IperionX embodies. The company is chasing low-cost US production of titanium powder, and its freshly released fiscal 2026 report shows just how expensive that ambition is in its current phase.
Losses double as Virginia runs around the clock
Net loss after tax nearly doubled to $66.8 million, up from $35.3 million a year earlier. Management's explanation is straightforward: spending on the titanium expansion was ratcheted up sharply, and the Virginia plant has shifted to a round-the-clock operating schedule. Running 24/7 consumes resources and lifts operating costs well before matching revenue arrives.
Revenue, for its part, remains absent. IperionX booked no sales in fiscal 2026 — nor in any of the four preceding fiscal years.
The stock has felt the weight of that growing capital need. Shares closed yesterday at EUR 1.46, and the year-to-date decline stands at 52%, leaving the paper hovering just above its 52-week low of EUR 1.38. Investors are pricing in the dilution and financing risks that inevitably accompany projects of this scale.
Should investors sell immediately? Or is it worth buying IperionX?
Capacity targets held firm
What matters most for the equity story is whether the medium-term roadmap survives contact with reality. Despite the wider loss, management reaffirmed its existing milestones. IperionX still aims for annual capacity of roughly 200 tonnes of titanium powder by the end of 2026, with installed capacity then reaching about 1,400 tonnes per year during 2027.
Theoretical capacity has already climbed from 125 to around 200 tonnes annually without additional investment, according to the company. Getting to the 1,400-tonne mark is a different order of magnitude: the planned expansion carries an estimated price tag of $75 million. Management is targeting unit costs of about $29/kg at full utilization, but that outcome demands substantial upfront outlays.
Additional backing comes from the IBAS-funded expansion at the Virginia site. Responding to a short-seller report, IperionX insisted the buildout is on schedule, with the goal of a sevenfold increase in nominal capacity to roughly 1,400 tonnes annually by mid-2027. For investors, that government flanking is an important signal that helps cushion the technological risk.
GenX validation, Army orders — and a crowded short side
The gap between strategic relevance and financial drought shapes sentiment on both sides. On the operational front, validation of the GenX platform for continuous titanium production arrived about two weeks ago: more than 500 kilograms of material was processed in 41 hours at the Virginia facility. Throughput in those test runs reached six times that of previous batch processes — proof the technology works in principle, though the platform still has to demonstrate profitable large-scale output.
Government tailwinds are real. Roughly a month ago, IperionX secured Task Order 2 from the U.S. Army under a domestic titanium program, a framework agreement allowing cumulative government orders of up to $99 million.
Skepticism, however, is building elsewhere. Media reports put the short interest at 13.5% of the free float. On the other side of the ledger, top management is signaling confidence: over a 90-day window, the two most senior executives net-bought roughly 664,000 shares worth a total of AUD 2.4 million.
A classic proving ground
Analyst coverage has adjusted to the new risk picture. Shabalin kept a buy rating but made a drastic cut to the price target, acknowledging the changed perception of risk rather than abandoning the thesis.
IperionX now faces a textbook test of industrial ramp-up: technological validation is advancing, but financial stamina will decide the outcome. Should the company hit its 2026 and 2027 capacity targets on time, today's loss line may read in hindsight as a necessary investment. Until then, the shares remain an engagement for those willing to sit through the customary dry spell of a manufacturing scale-up. The strategic value of an independent titanium supply chain is not in question — whether IperionX bridges the commercial gap without further friction depends on how quickly it can scale.
Ad
IperionX Stock: New Analysis - 2 October
Fresh IperionX information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
